cyrilzakka/clinical-trials huggingface dataset:
The Establishment of Tongue Examination Analysis From the Video Recording

This project intends to record the process of tongue extension through a dynamic video, and establish the tongue examination analysis from the video recording.

In this study, 300 general public will be invited for examinations, and high-quality tongue examination videos will be recorded by digital cameras. After the tongue examination video is properly calibrated, the computer analyzes the tongue examination parameters of each frame and the dynamic parameters, thereby establishing the automatic tongue video analysis system

Traditional Chinese medicine (TCM) doctors use tongue examination to investigate the distribution of qi and blood in the human body and the changes in cold and heat, deficiency and excess. This is a characteristic diagnosis of Chinese medicine and is rich in important clinical diagnostic information. In recent years, tongue examination through computer image analysis has been a fairly mature technology, but its application still has many limitations. A proper tongue examination image capture must be performed by a well-training staff, and errors caused by the operator cannot be avoided. These restrictions are not conducive to the popularization of tongue examination applications. This project intends to record the process of tongue extension through a dynamic video, and establish the tongue examination analysis from the video recording.

In this study, it is estimated that 300 subjects will be admitted to the China Medical University and its cooperative medical facilities. The general public will be invited for examinations, and high-quality tongue examination videos will be recorded by digital cameras. After the tongue examination video is properly calibrated, the computer analyzes the tongue examination parameters of each frame and the dynamic parameters, thereby establishing the automatic tongue video analysis system.

This study is different from recording the tongue with photos in the past, but uses dynamic movies to record the tongue extension process, avoiding the influence of external light source and tongue placement, seeking the best timing for tongue diagnosis, and it is expected to produce automatic dynamic video tongue examination analysis, as an innovative analysis model of TCM tongue examination. Results are expected to reduce operating errors and promote the popularization of automated tongue examination analysis. In the future, it may be applied to mobile phones or wearable devices to improve the practicality of TCM tongue examination in telemedicine and the personalized medicine.

Eligibility Criteria:
Inclusion Criteria:

* general public

Exclusion Criteria:

* unable to complete tongue examination
Evaluate the Migration Potential of Xeomin® Compared to Two Other Botulinum Toxin Type A Products

Xeomin® is a Botulinum neurotoxin type A preparation free of complexing proteins, i.e. free of bacterial proteins other than the active toxin. Injected into the muscle, Xeomin® causes local weakening. Botulinum toxin type A is used for certain neurological and aesthetic treatments. This study will investigate the migration potential of Xeomin®.

Conducted in Europe

Eligibility Criteria:
Inclusion Criteria:

* Healthy females, 18 to 65 years
European Union (EU) Post-Market Study on Easyband®

The purpose of this study is to collect additional safety, performance and effectiveness data of the Easyband gastric band medical device in the treatment of morbid obesity in 4 European countries where the device is a CE marked approved product.


Eligibility Criteria:
Inclusion Criteria:

* Demonstrated failure in losing weight with non-invasive therapies
* BMI ≥ 40 kg/m2, or BMI ≥ 35 kg/m2 and \< 40 kg/m2 with one or more significant medical conditions related to obesity

Exclusion Criteria:

* patients with BMI greater than 60 kg/m2
* patients who are not indicated for laparoscopic bariatric surgery
* patients with known allergies to implant materials such as silicone and PEEK
* patients whose abdominal structures have been damaged during preceding surgical procedures
* pregnant women
* patients under the age of 18 years
* patients treated with steroids
* patients addicted to alcohol or drugs, or who are mentally unstable, or who may not comply with the follow-up and dietary restrictions
* patients already implanted with a device sensitive to radio-frequency emissions such as implanted pacemaker, defibrillators, cochlear implants, implantable pumps etc
Validation of a Simplified Severity Score (Investigator Global Assessment: IGA) in Bullous Pemphigoid

The aim of the study is to validate a global and simple score : IGA (Investigator Global Assessment) score for the evaluation of the extent and severity of the disease in patients with bullous pemphigoid


Eligibility Criteria:
Inclusion Criteria:

* Consecutive adult patients aged ≥ 18 years
* Newly diagnosed or relapsing BP
* Clinical features suggestive of classic BP AND suggestive histological features AND deposition of IgG and/ or C3 deposits on the dermal epiderma junction, AND detection of circulating anti-epidermal antibodies labelling the epidermal side of salt-split skin
* Patient having read and understood the information letter and not opposed to participation
* Must be willing and able to adhere to all specified requirements, including but not limited to adherence to the follow-up visits

Exclusion Criteria:

* Predominant or exclusive mucosal involvement leading to suspect the diagnosis of mucous membrane pemphigoid
* Pemphigoid gestationis
* Linear IgA dermatosis (predominant or exclusive IgA deposits on the DEJ)
* Skin lesions suggesting the diagnosis of epidermolysis bullosa acquisita (skin fragility, atrophy, milia)
The Validity and Reliability Study of Turkish Version of Body Perception Questionnaire

The present study aims to determine the validity and reliability of the Turkish version of the Body Perception Questionnaire (BPQ) through the Turkish translation of the questionnaire and the intercultural adaptation. The Body Perception Questionnaire (BPQ) is a self-report measure of body awareness and autonomic reactivity. Its items are based on the organization of the autonomic nervous system (ANS), a set of neural pathways connecting the brain and body.

The present study aims to determine the validity and reliability of the Turkish version of the "Body Perception Questionnaire (BPQ) through the Turkish translation of the questionnaire and the intercultural adaptation. The Body Perception Questionnaire (BPQ) is a self-report measure of body awareness and autonomic reactivity. Its items are based on the organization of the autonomic nervous system (ANS), a set of neural pathways connecting the brain and body. These pathways send information from the body about the status of organs and tissues (i.e., afferent projections). Some of these incoming signals form a basis for the subjective awareness of the body. The ANS also carries signals that control the functions of these organs and tissues (i.e., efferent projections). These signals can alter the functions of the body, depending on internal and external needs. The study includes 175 healthy participants and 120 participants with anxiety. Beaton's 6-step procedure was used for translation and intercultural adaptation. After the steps of the procedure were completed, the questionnaire was finalized.

Eligibility Criteria:
Inclusion Criteria:

* Being a volunteer to participate in the study
* Being between the age of 18 - 77
* Understand and follow commands
* Not diagnosed a psychiatric disorder

Exclusion Criteria:

* Younger than the age of 18
* Reported taking psychotropic drugs and/or beta-blockers
* Did not complete the questions
* Having any surgical operation in the last six months
* Diagnosed chronic cardiovascular, pulmonary or neuromuscular systemic disorder
Anastomotic Leakage After Anterior Resection for Rectal Cancer - Predictive Biomarkers and Rectal Blood Flow

The purpose of this study is to determine whether reduced rectal blood flow is associated with the extent of surgery when performing an operation to remove rectal cancer. The investigators also aim to describe any relation of reduced rectal blood flow, as well as raised inflammatory biomarkers in blood and tissue, to the occurrence of anastomotic leakage. The patients will be recruited at Umeå University Hospital and all patients who are planned to undergo anterior resection for rectal cancer and able to consent are eligible for this study. Rectal blood flow measurements will be conducted with Laser-Doppler technology using noninvasive measuring probes. Preoperative and postoperative blood sampling as well as postoperative drain fluid collection will take place. Perianastomotic tissue will also be collected. In the postoperative period, any occurrence of surgical complications especially anastomotic leakage, will be noted. Blood flow and biomarkers will be assessed in relation to type of mesorectal excision (total or partial) and correlated to anastomotic leakage. Standard statistical tools will be utilized, such as parametric, non-parametric tests and logistic regression, as appropriate. The study will recruit approximately 40 patients during three consecutive years.


Eligibility Criteria:
Inclusion Criteria:

* Planned anterior resection for rectal cancer
* Willing to participate

Exclusion Criteria:

* Not willing to participate
* Unable to consent
The Volume of Blood Submitted for Culture in Neonates - a Multicentre Quality Improvement Initiative.

The study will examine if introducing the practice of checking the volume of blood culture samples in neonates by bedside weighing will improve the sensitivity of the test and increase confidence in negative results affecting the rate of extended antibiotic treatment in neonates with negative blood cultures.

In the first part of the study (pre-intervention) the actual volumes of blood submitted for culture in neonates from participating neonatal units will be examined for the period of six months. The culture vials will be pre-weighted using precision scale before delivery to the units. After collecting the sample the vials will be weighted again at the time of admission to microbiology laboratory. At the end of the first phase, the results will be revealed to clinical teams and discussed. The sample volume control by using bedside precision scale will be introduced to the participating units along with educational actions to raise the awareness of importance of collecting adequate volume of blood for culture. The minimum volume of blood will be defined as at minimum 1 ml. The paramount role of blood culture in process of ruling out newborn sepsis will be emphasized. In the second phase of the study clinicians in participating centres will have an opportunity of measuring the volume of samples just after collecting. The volumes will also be independently controlled in the microbiology laboratory. The second phase will also last six months. Collected volumes will be compared to results from pre-intervention period. Clinical outcome measured by frequency of antibiotic treatment in newborn patients with negative blood culture will be compared before and after implemented changes. We hypothesize that introducing routine bedside control of the blood volume submitted for culture will result in increase confidence in negative blood culture results and decrease of antibiotic use in newborn population.

Eligibility Criteria:
Inclusion Criteria:

- Any infant in a neonatal ward who has a blood culture collected (either early-onset or late-onset sepsis suspected).

Exclusion Criteria:

- There is no exclusion criteria.
PROGNOSTIC ROLE OF SERUM ALBUMIN LEVEL IN RADIOLOGICAL PROGRESSION OF GONARTHROSIS: IS IT A BIOMARKER IN ITSELF? A BIOMARKER ASSOCIATED WITH SYSTEMIC INFLAMMATION?

The aim of our study is to evaluate the prognostic roles of serum albumin level and systemic inflammation-related indices, including and not including serum albumin level, in the radiological progression of gonarthrosis. In this retrospective study, between 10.01.2017 and 10.01.2022, the data of the patients between the ages of 50-80, who applied to Ufuk University Physical Medicine and Rehabilitation clinic with the complaint of knee pain and met the clinical criteria of the American Rheumatology Association for gonarthrosis (knee osteoarthritis) (knee pain on many days of the previous month, crepitation with active joint movement, morning stiffness lasting ≤ 30 minutes, age ≥38 years, bone enlargement of the knee on examination),and whose knee radiography and blood tests were evaluated at admission were scanned.


Eligibility Criteria:
Inclusion Criteria:

* In this retrospective study, between 10.01.2017 and 10.01.2022, the data of the patients between the ages of 50-80, who applied to Ufuk University Physical Medicine and Rehabilitation clinic with the complaint of knee pain and met the clinical criteria of the American Rheumatology Association for gonarthrosis (knee osteoarthritis) (knee pain on many days of the previous month, crepitation with active joint movement, morning stiffness lasting ≤ 30 minutes, age ≥38 years, bone enlargement of the knee on examination),and whose knee radiography and blood tests were evaluated at admission were scanned. In order to compare the parameters to be included in the study, the data and blood tests of patients between the ages of 50-80 who applied to Ufuk University Physical Medicine and Rehabilitation clinic between 10.01.2017 and 10.01.2022 for reasons other than knee pain were scanned.

Exclusion Criteria:

* In the patient and control groups, patients who were younger than 50 years of age, older than 80 years of age, had acute or chronic infection, malignancy, rheumatic disease or systemic diseases that could change the blood test parameters to be evaluated, and patients who were missing one or more of the blood test parameters planned to be evaluated among the data obtained were excluded from the study. In addition, in the patient group, patients who had neurogenic or internal organ problems that could cause pain referred to the knees, who were not required to have a knee X-ray when applying to the outpatient clinic, and who had a history of trauma to the knee area, invasive procedure or surgical intervention within the 6 months before admission to the outpatient clinic, were excluded from the study. In the control group, patients who complained of knee pain in addition to their complaints at admission were excluded from the study.
Very Long Versus Overlapping Stents in Long Coronary Lesions

This study is performed to compare the angiographic and clinical outcomes of the use of single long stent versus overlapping stents in the treatment of long coronary lesions in patients with chronic coronary syndrome.

Percutaneous coronary intervention (PCI) in diffuse coronary artery disease is still considered a big obstacle for interventional cardiologists. Very long coronary lesions are usually found, and implantation of a single stent was a great problem forcing the operator to do overlapping of several stents.

Recently, new stent designs with increasing length are developed and emerging as a great tool for the percutaneous treatment of long lesions. Nowadays, stents up to 60 mm are available to be used in these cases reducing stent overlap.

Intravascular ultrasound (IVUS)-guided percutaneous coronary intervention has been shown in clinical trials, registries, and meta-analyses to be associated with a reduction in clinical events after percutaneous coronary intervention; however, IVUS utilization during percutaneous coronary intervention remains low in the United States and worldwide. The impact of IVUS in these complex lesions may be associated with a lower rate of clinical adverse events in comparison with angiography alone.

The study will be conducted on forty patients with chronic stable angina on maximal medical treatment who are going to have elective coronary angiography and elective PCI and having one long coronary lesion that is more than 40 mm in length, they will be randomized into either treatment of the lesion with a single very long stent (more than 40 mm in length) or with more than one overlapping stents in 1:1 randomization. Control angiography and IVUS will be done to the 2 groups after 6 months and the major cardiovascular outcomes will be addressed at 1,3 and 6 months follow-up periods.

Eligibility Criteria:
Inclusion Criteria:

* Patients \> 18 years of age
* Single vessel disease and undergoing PCI for significant long lesion.
* Chronic stable angina on maximal medical treatment.

Exclusion Criteria:

* Patients presenting with acute coronary syndromes.
* Patients having two or more vessel disease on coronary angiography.
* Previous myocardial infarction.
* Previous vascularization either by PCI or bypass grafting.
* Very low ejection fraction less than 35%.
* Renally impaired patients with Creatinine clearance less than 50 ml/min.
* Contraindication to dual antiplatelet drug therapy.
* Contraindication to coronary angiography.
Effect of Duloxetine and Venlafaxine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol: A Three-phase Randomized Balanced Cross-over Study in Healthy Volunteers

Tramadol is an opioid analgesic, which is widely used in the treatment of acute and neuropathic pain. After oral administration, tramadol is rapidly and almost completely absorbed. Tramadol is extensively metabolised by O- and N-demethylation, which are catalysed by the liver CYP-450 enzymes. O-desmethyltramadol is an active metabolite and its formation is catalysed by CYP2D6. This study is aimed to investigate the possible interaction of oral tramadol with duloxetine and venlafaxine. Duloxetine is known to inhibit CYP2D6. Twelve healthy male or female adult non-smoking volunteers aged 18-40 years with body weights within ±15% of the ideal weight for height are taken into the study. Primary endpoints of the study are plasma concentrations of tramadol and its metabolites.


Eligibility Criteria:
Inclusion Criteria:

* Healthy volunteers
* Age 18-40
* Body weight within ±15% of the ideal weight for height

Exclusion Criteria:

* A previous history of intolerance to the study drugs or to related compounds and additives
* Concomitant drug therapy of any kind for at least 14 days prior to the study
* Existing or recent significant disease
* History of hematological, endocrine, metabolic or gastrointestinal disease, including gut motility disorders
* History of asthma or any kind of drug allergy
* Previous or present alcoholism, drug abuse, psychological or other emotional problems that are likely to invalidate informed consent, or limit the ability of the subject to comply with the protocol requirements
* A positive test result for urine toxicology
* A "yes" answer to any one of the Abuse Questions
* Pregnancy or nursing
* Donation of blood for 4 weeks prior and during the study
* Special diet or life style conditions which would compromise the conditions of the study or interpretation of the results
* Participation in any other studies involving investigational or marketed drug products concomitantly or within one month prior to the entry into this study
* Smoking for one month before the start of the study and during the whole study period
* Any history of coagulation abnormality, also in first degree relatives
Immune Checkpoint Inhibitors Rechallenge After Immune-related Adverse Events

Although immune checkpoint inhibitors (ICIs) have proved effective in treating many cancers, patients receiving ICIs may experience immune-related adverse events (irAEs). Little evidence exists on the safety of resuming these treatments after an irAE.

Our objective was to investigate the safety of ICI rechallenge after an irAE using the WHO pharmacovigilance database


Eligibility Criteria:
Inclusion Criteria:

* Case reported in the World Health Organization (WHO) database (VigiBase) of individual safety case reports at the time of the extraction,
* consecutive individual case safety reports present in VigiBase reporting an irAEs associated to at least one immune checkpoint inhibitor.

Exclusion Criteria:

* Chronology not compatible between the drug and the toxicity.
Analysis of Complementary Exams Prescriptions From an Emergency Unit of a University Hospital

The objective of this study is to evaluate the appropriateness of prescribing additional tests in the emergency unit of the University Hospital of Monastir.

The objective of this study is to evaluate the appropriateness of prescribing additional tests in the emergency unit of the University Hospital of Monastir.

Eligibility Criteria:
Inclusion Criteria:

* all patients consulting Emergency Department of Monastir aged more than 1 year

Exclusion Criteria:

* age \< 1 year
Bone UltraSonic Scanner (BUSS) Clinical Optimization Study

The aim of this clinical study using Bone UltraSonic Scanner (BUSS) is to obtain clinical data which will help to optimize the BUSS examination procedure and its diagnostic algorithms for assessment of bone conditions.

The specific aims of this clinical study are:

1. To optimize the data collection technique and establish an examination procedure;
2. To collect data necessary for assessing the performance of BUSS sensors;
3. To evaluate the probe ergonomic design and participant tolerance to probe application;
4. To assess the clinical suitability of the software interface in data collection;
5. To adjust the BUSS diagnostic algorithms using dual-energy X-ray absorptiometry (DEXA) data as a "gold" standard in osteoporosis detection and characterization;
6. To evaluate BUSS performance including ease of use and consistency.

Eligibility Criteria:
Inclusion Criteria:

Any race or ethnical group DEXA examination scheduled within next two weeks or DEXA examination was completed within the last six months adn DEXA results are available

Exclusion Criteria:

Open wounds or rashes on the tibial testing area Active skin infection Recent tibia surgery Abnormal tibia Anatomy Current or previous tibial fracture Body Mass Index \>34.9 Hyperparathyroidism or hypoparathyroidism within 5 years Osteitis deformans Renal osteodystrophy Osteomalacia Stroke with total or partial paralysis with residual disability lasting more than 3 months Current or recent (within past 6 months) use of bone-active drugs Drugs under research protocols Chronic use of over the counter antacids

-